Boccadoro, M. (Mario)

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
    (Springer Nature, 2018) Kaiser, M. (Martin); Moreau, P. (Philippe); Weisel, K. (Katja); Boccadoro, M. (Mario); Delforge, M. (M.); Engelhardt, M. (Monika); Bladé, J. (Joan); Cavo, M. (Michele); Jackson, G.H. (Graham H.); Zweegman, S. (Sonja); Mellqvist, U. (Ulf); Ludwig, H. (Heinz); Hajek, R. (R.); Mateos, M.V. (María Victoria); Sonneveld, P. (Pieter); Beksac, M. (Meral); Mohty, M. (Mohamad); Einsele, H. (Hermann); Donk, N.W.C.J. (Niels W.C.J.) van de; Facon, T. (Thierry); Goldschmidt, H. (Hartmut); Dimopoulos, M.A. (Meletios A.); Gay, F. (Francesca); Waage, A. (Anders); Avet-Loiseau, H. (Herve); Caers, J. (Jo); Terpos, E. (Evangelos); Driessen, C. (Cristoph); San-Miguel, J.F. (Jesús F.); Cook, G. (Gordon); Leleu, X. (Xavier); Garderet, L. (Laurent)
    During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.
  • Thumbnail Image
    Insights on multiple myeloma treatment strategies
    (Ovid Technologies (Wolters Kluwer Health), 2018) Moreau, P. (Philippe); Hansson, M. (Markus); Boccadoro, M. (Mario); Delforge, M. (M.); Straka, C. (Christian); Bladé, J. (Joan); Masszi, T. (Tamás); Cavo, M. (Michele); Ludwig, H. (Heinz); Hajek, R. (R.); Mateos, M.V. (María Victoria); Zver, S. (Samo); Jamroziak, K. (Krzysztof); Sonneveld, P. (Pieter); Beksac, M. (Meral); O’Dwyer, M. (Michael); Bazarbachi, A. (Ali); Yong, K. (Kwee); Donk, N.W.C.J. (Niels W.C.J.) van de; Geraldes, C. (Catarina); Facon, T. (Thierry); Goldschmidt, H. (Hartmut); Dimopoulos, M.A. (Meletios A.); Mendeleeva, L. (Larisa); Plesner, T. (Torben); Leiba, M. (Merav); San-Miguel, J.F. (Jesús F.)
    The introduction of new agents and management strategies over the past decade has resulted in a major step change in treatment outcomes with deepening responses and increased survival for patients with multiple myeloma. In daily clinical practice, healthcare professionals are now faced with challenges including, optimal treatment sequencing and changing treatment goals. In light of this, a group of experts met to discuss diagnostic and treatment guidelines, examine current clinical practice, and consider how new clinical trial data may be integrated into the management of multiple myeloma in the future.
  • Thumbnail Image
    Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
    (2023) Moreau, P. (Philippe); Boccadoro, M. (Mario); Delforge, M. (M.); Engelhardt, M. (Monika); Schjesvold, F.H. (Fredrik H.); Ntanasis-Stathopoulos, I. (Ioannis); Zweegman, S. (Sonja); Ludwig, H. (Heinz); Hajek, R. (R.); Sonneveld, P. (Pieter); Einsele, H. (Hermann); Donk, N.W.C.J. (Niels W.C.J.) van de; Dimopoulos, M.A. (Meletios A.); Gay, F. (Francesca); Terpos, E. (Evangelos); Driessen, C. (Cristoph); Vangsted, A.J. (Annette Juul); San-Miguel, J.F. (Jesús F.); Cook, G. (Gordon)
    In the post-pandemic COVID-19 period, human activities have returned to normal and COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an increased risk for breakthrough infections and severe COVID-19 outcomes, including hospitalization and death. The European Myeloma Network has provided an expert consensus to guide patient management in this era. Vaccination with variant-specific booster vaccines, such as the bivalent vaccine for the ancestral Wuhan strain and the Omicron BA.4/5 strains, is essential as novel strains emerge and become dominant in the community. Boosters should be administered every 6-12 months after the last vaccine shot or documented COVID-19 infection (hybrid immunity). Booster shots seem to overcome the negative effect of anti-CD38 monoclonal antibodies on humoral responses; however, anti-BCMA treatment remains an adverse predictive factor for humoral immune response. Evaluation of the immune response after vaccination may identify a particularly vulnerable subset of patients who may need additional boosters, prophylactic therapies and prevention measures. Pre-exposure prophylaxis with tixagevimab/cilgavimab is not effective against the new dominant variants and thus is no longer recommended. Oral antivirals (nirmatrelvir/ritonavir and molnupiravir) and remdesivir are effective against Omicron subvariants BA.2.12.1, BA.4, BA.5, BQ.1.1 and/or XBB.1.5 and should be administered in MM patients at the time of a positive COVID-19 test or within 5 days post symptoms onset. Convalescent plasma seems to have low value in the post-pandemic era. Prevention measures during SARS-CoV-2 outbreaks, including mask wearing and avoiding crowded places, seem prudent to continue for MM patients.